Resonant, a subsidiary of Renew Biotechnologies, has been recognized with the 'DNA Sequencing Innovation Of The Year' honor at the BioTech Breakthrough Awards for its development of a novel blood-based diagnostic platform.
Resonant's technology utilizes nanopore sequencing to analyze cell-free DNA in the blood. The innovation specifically focuses on methylation patterns that can be traced back to their cellular origins within the central nervous system. This approach allows the test to identify and quantify the death of specific neuron and glial cell types — such as cortical or dopaminergic neurons — which are associated with conditions like Alzheimer's and Parkinson's disease.
Resonant's blood-based diagnostic platform avoids certain chemical processing steps and aims to preserve the original biological data.
Award-Winning Blood-Based Diagnostic Platforms
The BioTech Breakthrough Awards Recognizes Resonant
Trend Themes
-
Nanopore Sequencing Diagnostics — Nanopore sequencing innovations are redefining how cell-free DNA is analyzed, opening new avenues for precise medical diagnostics.
-
Cns-originated Methylation Detection — Detecting methylation patterns linked to the central nervous system offers groundbreaking insights for early intervention in neurodegenerative diseases.
-
Preservation-focused Diagnostic Methods — Methods that prioritize the preservation of original biological data are disrupting traditional diagnostic processes by enhancing the accuracy of health assessments.
Industry Implications
-
Biotechnology — Biotechnology is undergoing a paradigm shift with advancements in non-invasive diagnostic tools that promise to transform disease detection and monitoring.
-
Healthcare Diagnostics — The healthcare diagnostics industry is being revolutionized by blood-based platforms that offer earlier and more precise disease identification.
-
Neuroscience — Neuroscience is poised for breakthroughs with the ability to non-invasively assess neuron health and degeneration, facilitating proactive neurological care.